Recap: Abbott Laboratories Q2 Earnings

Benzinga Insights
July 16, 2020

Shares of Abbott Laboratories (NYSE:ABT) rise 1.7% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were down 30.49% over the past year to $0.57, which beat the estimate of $0.41.

Revenue of $7,328,000,000 decreased by 8.16% year over year, which beat the estimate of $6,750,000,000.

Looking Ahead

For 2020, the company expects adjusted earnings of "at least" $3.25 per share.

How To Listen To The Conference Call

Date: Jul 16, 2020

Time: 09:30 AM

ET Webcast URL:

Price Action

52-week high: $100.00

Company's 52-week low was at $61.61

Price action over last quarter: down 0.04%

Company Profile

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.